Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.196
Neutral
RSI(14)
50.844
Neutral
STOCH(KDJ)(9,3,3)
75.383
Neutral
ATR(14)
0.677
Low Volatility
CCI(14)
71.740
Neutral
Williams %R
37.039
Buy
TRIX(12,20)
-0.237
Sell
StochRSI(14)
57.625
Sell
Addex Therapeutics Ltd
ADXN8.000USD
-0.380-4.53%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
7.77MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Addex Therapeutics Ltd
Currency: USD Updated: 2025-12-24Key Insights
Addex Therapeutics Ltd's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 243/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 30.00.In the medium term, the stock price is expected to trend down.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Addex Therapeutics Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
30.000
Target Price
+243.64%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Addex Therapeutics Ltd Highlights
StrengthsRisks
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Growing
The company is in a growing phase, with the latest annual income totaling USD 465.76K.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Undervalued
The company’s latest PE is -0.98, at a low 3-year percentile range.
Financial Health
Currency: USD Updated: 2025-12-24The current financial score of Addex Therapeutics Ltd is 6.09, ranking 300/404 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 62.01K, representing a year-over-year decrease of 7.97%, while its net profit experienced a year-over-year decrease of 11.60%.
Score
Financials
8.11
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.83
Operational Efficiency
2.83
Growth Potential
5.61
Shareholder Returns
7.07
Addex Therapeutics Ltd's Company Valuation
Currency: USD Updated: 2025-12-24The current valuation score of Addex Therapeutics Ltd is 1.00, ranking 399/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.98, which is -360.59% below the recent high of 2.55 and -56.60% above the recent low of -1.53.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 243/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-24No earnings forecast score is currently available for Addex Therapeutics Ltd. The Biotechnology & Medical Research industry's average is 8.02. The average price target for Addex Therapeutics Ltd is 30.00, with a high of 30.00 and a low of 30.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
No Data
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-24The current price momentum score of Addex Therapeutics Ltd is 6.63, ranking 231/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 9.12 and the support level at 7.14, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
8.132
Sell
MA10
7.938
Buy
MA20
7.964
Buy
MA50
8.497
Sell
MA100
8.471
Sell
MA200
8.303
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-24Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2025-12-24The current risk assessment score of Addex Therapeutics Ltd is 1.51, ranking 326/404 in the Biotechnology & Medical Research industry. The company's beta value is 1.49. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.49
VaR
+9.07%
240-Day Maximum Drawdown
+100.00%
240-Day Volatility
--
Return
Best Daily Return
60 days
+28.37%
120 days
--
5 years
--
Worst Daily Return
60 days
-17.90%
120 days
-100.00%
5 years
-100.00%
Sharpe Ratio
60 days
+0.34
120 days
--
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+100.00%
3 years
+100.00%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
+0.09
3 years
-0.24
5 years
-0.19
Skewness
240 days
--
3 years
--
5 years
--
Volatility
Realised Volatility
240 days
--
5 years
--
Standardised True Range
240 days
+8.55%
5 years
+46.95%
Downside Risk-Adjusted Return
120 days
--
240 days
--
Maximum Daily Upside Volatility
60 days
+115.63%
Maximum Daily Downside Volatility
60 days
+78.08%
Liquidity
Average Turnover Rate
60 days
--
120 days
--
5 years
--
Turnover Deviation
20 days
--
60 days
--
120 days
--
Peer Comparison
Biotechnology & Medical Research
Addex Therapeutics Ltd
ADXN
3.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Dynavax Technologies Corp
DVAX
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Addex Therapeutics Ltd?
The TradingKey Stock Score provides a comprehensive assessment of Addex Therapeutics Ltd based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Addex Therapeutics Ltd’s performance and outlook.
How do we generate the financial health score of Addex Therapeutics Ltd?
To generate the financial health score of Addex Therapeutics Ltd, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Addex Therapeutics Ltd's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Addex Therapeutics Ltd.
How do we generate the company valuation score of Addex Therapeutics Ltd?
To generate the company valuation score of Addex Therapeutics Ltd, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Addex Therapeutics Ltd’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Addex Therapeutics Ltd’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Addex Therapeutics Ltd.
How do we generate the earnings forecast score of Addex Therapeutics Ltd?
To calculate the earnings forecast score of Addex Therapeutics Ltd, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Addex Therapeutics Ltd’s future.
How do we generate the price momentum score of Addex Therapeutics Ltd?
When generating the price momentum score for Addex Therapeutics Ltd, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Addex Therapeutics Ltd’s prices. A higher score indicates a more stable short-term price trend for Addex Therapeutics Ltd.
How do we generate the institutional confidence score of Addex Therapeutics Ltd?
To generate the institutional confidence score of Addex Therapeutics Ltd, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Addex Therapeutics Ltd’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Addex Therapeutics Ltd.
How do we generate the risk management score of Addex Therapeutics Ltd?
To assess the risk management score of Addex Therapeutics Ltd, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Addex Therapeutics Ltd’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Addex Therapeutics Ltd.
